ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer
ASO Author Reflections
- 20 Downloads
Authors declare that he has no conflicts of interest.
- 2.Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.CrossRefGoogle Scholar
- 3.Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28:1829–34.CrossRefGoogle Scholar
- 5.Wang M, Wu K, Zhang P, et al. The prognostic significance of Oncotype DX recurrence score in T1-2N1M0 ER-positive HER2-negative breast cancer based on the prognostic stage in the updated AJCC 8th edition. Ann Surg Oncol. 2018. https://doi.org/10.1245/s10434-018-7068-3.
© Society of Surgical Oncology 2019